CASE REPORT

Morbilliform eruption in a patient receiving intravesical Bacilli Calmette-Guérin

Holly Reid, BS,a Savina Aneja, MD,b and Susan Y. Chon, MDb
Houston, Texas

Keywords: BCG immunotherapy; BCG-osis; BCG vaccine; drug eruption; morbilliform drug eruption.

INTRODUCTION
Widely known as a vaccine against tuberculosis, Bacilli Calmette-Guérin (BCG) is also known to have antimalignant properties. Intravesical BCG immunotherapy is used in the treatment of superficial bladder cancer. It is postulated that the BCG bacilli trigger a cascade that leads to increased levels of interleukin-12 and interferon gamma production, which mediate tumor destruction.1 Major side effects occur in less than 5% of those treated and are secondary to dissemination of the bacilli through vesicoureteral reflux or hematogenous spread.2

CASE REPORT
A 63-year-old white man with urothelial carcinoma of the bladder undergoing intravesical Tice BCG treatments had a pruritic cutaneous eruption on his right arm and a subjective fever 1 day after his third instillation of intravesical BCG. Two days later, parotid gland enlargement developed, and the patient was given ampicillin by his primary care physician for possible parotitis. After 1 dose of ampicillin, the eruption spread to his trunk and face. The physician administered a steroid injection and switched the medication to ciprofloxacin, which resulted in temporary improvement of symptoms.

Four days later, when the patient presented to the urology clinic for his fourth instillation of intravesical BCG, he was febrile, so the treatment was withheld. Several hours later he had chills, myalgias, and recurrence of his skin eruption.

On physical examination, he was noted to have multiple pink macules coalescing into patches involving approximately 30% of the back and 20% of the anterior trunk and multiple 2- to 6-cm macules and papules on the bilateral upper and lower extremities (Fig 1). A punch biopsy found sparse superficial perivascular dermatitis with focal minimal spongiosis, consistent with a dermal hypersensitivity reaction.

Increasing clinical suspicion of systemic hypersensitivity reaction to BCG dissemination prompted the initiation of antituberculous therapy with isoniazid, rifampin, and levofloxacin. After 1 week of therapy, the patient experienced symptomatic improvement, so this regimen was continued for 3 months, and he had complete resolution. Further

Abbreviation used:
BCG: Bacilli Calmette-Guérin

Fig 1. BCG-osis. Widespread light pink macules and papules on the anterior trunk.

Medical Student at The University of Texas Medical School at Houstona and Department of Dermatology, University of Texas MD Anderson Cancer Center.b
Funding sources: None.
Conflicts of interest: None declared.
Correspondence to: Susan Y. Chon, MD, Department of Dermatology, University of Texas at Houston and MD Anderson Cancer Center, 6655 Travis Street, Suite 600, Houston, Texas 77030. E-mail: susanchon@mdanderson.org.

JAAD Case Reports 2015;1:30-1.
2352-5126
© 2015 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
http://dx.doi.org/10.1016/j.jdcr.2014.10.004